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Background: There has been a recent increase in the use of biologics in hip arthroscopy to assist in the management of fem-
oroacetabular impingement (FAI).
Purpose: To analyze the current use of biologics for the treatment of FAI and its associated lesions.
Study Design: Systematic review; Level of evidence, 4.
Methods: A search of the PubMed, Medline, and EMBASE databases was performed inMarch 2019 with use of the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The criterion for inclusion was observational, published
research articles studying the therapeutic use of biologics as an adjuvant therapy during arthroscopic surgery for FAI; treatments
included bone marrow aspirate concentrate, mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), hyaluronic acid, growth
factors, and autologous chondrocyte implantation (ACI) or autologous matrix-induced chondrogenesis (AMIC).
Results: There were 9 studies that met the inclusion criteria, and a total of 674 patients were included across all studies. FAI was
studied in all articles. Further, 7 studies (78%) also analyzed chondral injuries, and 3 studies also analyzed labral tears (33%). ACI or
AMIC was used in 56% of studies and showed superior functional outcomes at short- and midterm follow-up versus debridement
or microfracture. PRP did not improve the outcome of labral repairs at short-term follow-up.
Conclusion: The current literature regarding biologic adjuncts in hip arthroscopy is varied in quality, with only one level 1 study.
The use of ACI/AMIC for medium-sized chondral lesions showed promising results in individual studies; however, these were of
lower quality. To enable comparisons among future studies, investigators must ensure accuracy in the reporting of biologic
preparations and formulations used and homogeneity in the type and severity of lesion treated.
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Hip arthroscopy has shown great promise for the surgical
management of both intra-articular and extra-articular hip
lesions.16,36 In particular, arthroscopy has been shown to be
an effective treatment for femoroacetabular impingement
(FAI) syndrome, which is a well-recognized cause of hip
pain in the young, active population15,36 and the most com-
mon abnormality treated by hip arthroscopy.37 Other
lesions that have been treated by hip arthroscopy include
ligament teres tears,4 psoas tendon tears,44 and osteonecro-
sis of the femoral head.37 Labral tears, chondral injuries,
and osteoarthritis can often be secondary to FAI,1,2 and it is
possible to treat these during hip arthroscopy by surgical
techniques and/or biologics treatments.
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Biologics have become increasingly popular in orthopae-
dics and sports medicine over the past 20 years.21 These
agents aim to provide superior clinical outcomes by opti-
mizing and accelerating musculoskeletal tissue healing.
Current biologic treatments available include bone marrow
aspirate concentrate, culture-expanded mesenchymal stem
cells (MSCs) and stromal cells, autologous blood products
(including platelet-rich plasma [PRP]), growth factors, hya-
luronic acid, and autologous chondrocyte implantation
(ACI) or autologous matrix-induced chondrogenesis
(AMIC). Promising results have been shown in vitro with
respect to bone17 and cartilage regeneration.28 Results in
the clinical literature have been varied; however, encour-
aging results have been shown in a number of randomized
controlled trials in the treatment of both lateral epicondy-
litis13,27 and fracture healing.14
Despite the recent popularization of biologics in the
treatment of musculoskeletal conditions, there has been
substantial heterogeneity in the reporting of the prepara-
tion, concentration, and delivery of these agents. Murray
et al32 presented the range of PRP concentrations in a
recent review. The authors reported the concentration of
PRP in current commercial systems to range from 1.7 to
9.3 times the platelet concentration of whole blood. Robin-
son et al42 reported large variations in the source, concen-
tration, and delivery methods of MSCs within the current
orthopaedic literature.
The use of biologics in the treatment of hip joint abnor-
mality has predominantly focused on the management of
osteonecrosis of the femoral head,38 often in conjunction
with core decompression. A recent systematic review of
treatment of osteonecrosis of the femoral head concluded
that cell-based therapy was a safe treatment that provided
improved clinical outcomes and reduced disease progres-
sion.39 Many systematic reviews have analyzed the use of
biologics in other aspects of orthopaedic surgery, including
rotator cuff repair,6,18 anterior cruciate ligament recon-
struction,9,45 and tendinopathy.3,10,23,26,35 However,
despite the increasing use of biologics in hip arthroscopy
to treat FAI and its associated intra-articular abnormali-
ties, no systematic reviews have analyzed all relevant
studies.
The purpose of this study was to systematically review
the current literature reporting the use of biologics in the
management of FAI and its associated lesions and to com-
pare the outcomes of these studies.
METHODS
A search of PubMed, Medline, and EMBASE was per-
formed in March 2019 in line with the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses) statement.29 The study was registered using the
PROSPERO international prospective register of system-
atic reviews.
Titles and abstracts identified were independently
reviewed by 2 authors (P.G.R., P.G.), and those studies not
meeting the inclusion criteria were excluded before full-
text review. When the relevance of an abstract was in
doubt, the full text was subsequently reviewed. Unanimous
consensus was met among the authors regarding the inclu-
sion of proposed studies for full-text review. The studies
selected for full-text review were then further evaluated
against the inclusion and exclusion criteria. A search of the
references was performed of the selected studies to ensure
no other relevant studies were missed.
Search Terms and Criteria for Inclusion
The criteria for inclusion were observational published
research articles (randomized controlled trials, cohort,
cross-sectional, or case-control studies) and case series
studying the therapeutic use of biologics as adjuvant ther-
apy to arthroscopic surgery in the management of FAI;
treatments included bone marrow aspirate concentrate,
MSCs, PRP, hyaluronic acid, growth factors, and ACI or
AMIC. Studies were excluded if they were technical or
review articles, included synthetic bone matrices or bone
substitutes, or were not published in the English language.
For the biologic treatments studied in this review, 6 sepa-
rate searches were performed in each database. The search
terms were hip, femoroacetabular, impingement, arthros-
copy, platelet rich plasma, mesenchymal stem cells, bone
marrow aspirate, growth factors, hyaluronic acid, and
chondrocyte implantation. Detailed search term combina-
tions can be found in Appendix Table A1.
Data Extraction
The collected data from each study included the year of pub-
lication, study type, patient age, sex, body mass index, path-
ologic condition, type of surgery, size and severity of the
chondral lesion, severity of arthritis, biologic treatment
used, follow-up, outcomes, reoperation rate, conversion to
total hip arthroplasty (THA), and the level of evidence.
Outcome Measures and Analysis
The primary objective was to report the variety of biologic
treatments used and to compare clinical outcomes. Second-
ary objectives included reporting the spectrum of severity
of the pathologic condition treated, establishing ideal bio-
logic formulations for specific lesions, assessing complica-
tions, and analyzing the quality of the included studies.
Data analysis was primarily in the form of reporting vari-
ables collected in the data extraction process, and efforts
were made to consolidate data if they were comparable. A
meta-analysis was not performed because of the heteroge-
neous nature of the data in each included paper.
Quality Assessment
All studies were quality assessed by 2 authors (P.G.R.,
P.G.) using the NIH Quality Assessment Tool for Observa-
tional Cohort and Cross-Sectional Studies. The authors of
the assessment tool discourage users from allocating a spe-
cific score to each study. We have not given a traditional
“good,” “fair,” or “poor” rating to each study but have
instead given a percentage to the number of applicable
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questions answered “yes.” If there was disagreement
regarding the scoring of a study, consensus was met after
discussion among both assessors.
RESULTS
In the initial search of databases and reference lists, 1467
articles were identified. After initial screening of titles and
abstracts, 28 articles met the inclusion criteria for review.
On full-text screening, a further 19 studies were excluded
(Figure 1). A final 9 studies met the inclusion criteria and
are described in Table 1. The year of publication ranged
from 2012 to 2016. The studies included 3 case series, 1
retrospective cohort study, 3 prospective cohort studies,
and 2 randomized controlled trials. There were 3 high-
level studies: 1 study was level 1 and 2 studies were level
2. A total of 674 patients were included across all studies.
The mean patient age was 37.6 years (range, 16-60 years),
and the overall mean ratio of male to female participants
was 1 to 1.2. The mean length of follow-up was 34 months
(range, 12-74 months). There were 2 studies that reported
the mean body mass index, which was 25.5 (range, 25-26).
All studies used FAI as their minimum inclusion crite-
rion, which included assessment with plain radiographs
and magnetic resonance imaging (MRI). Biologic therapy
was used in the adjuvant treatment of labral repairs in 3
studies (33%), chondral injuries in 8 studies (89%), and
osteoarthritis in 1 study (11%). Of the studies examining
chondral injuries, all reported injuries to the acetabulum,
and 2 studies also examined femoral head defects (Table 2).
ACI was used in 4 studies (44%), AMIC in 2 studies (22%),
and PRP in 3 studies (33%). Bone marrow–derived MSCs
(BM-MSCs) were used in 1 study (11%). Further, 1 study
used both AMIC and ACI.
Details of the surgical techniques used to treat FAI were
described in 7 studies (78%). The mean proportion of
patients receiving acetabuloplasty was 37.8% (range, 0%-
100%), and the mean proportion receiving femoroplasty
was 60.8% (range, 38%-100%). There were 5 studies (56%)
that reported the method used to treat labral tears. Red-
mond et al41 performed a randomized controlled trial com-
paring PRP versus placebo in 306 patients with labral
tears. Labral repair was performed in 57% of patients, and
32% underwent labral debridement. This was the only
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram demonstrating selection
process for included studies.
The Orthopaedic Journal of Sports Medicine Current Use of Biologics for Treatment of FAI 3
study to report whether capsular closure or repair was
performed.
Injury and Osteoarthritis Severity
The presence of hip osteoarthritis was reported in 8 of the
included studies (89%). Tönnis grading was used in 5 stud-
ies (56%), and the Kellgren-Lawrence classification was
used in 1 study (11%). A further study excluded patients
with “severe osteoarthritis” but did not report how the
investigators defined this. LaFrance et al20 did not use a
recognized classification but did exclude patients with less
than 1 mm of joint space on anteroposterior or lateral hip
radiographs. With regard to the severity of the osteoarthri-
tis, 4 studies included patients with grade 2 or lower, on the
Tönnis grading system, and 1 study included grades 2 and
3. The study using the Kellgren-Lawrence classification
included grade 1 only.
Of the 8 studies reporting chondral injury, 4 studies
(50%) reported the size of the lesions treated. The mean
size was 3.4 cm2 (range, 2-8 cm2) (Table 2). The Outerbridge
classification was used to grade the chondral lesions in 5
studies (56%), in which all studies included grades 3 or 4.
One further study used the International Cartilage Repair
Society score and included grades 3 and 4. Acetabular and
femoral locations of the chondral injuries were reported in 2
studies (25%).
Details of Biologics Used
All studies performing ACI used a 3-dimensional tech-
nique. Körsmeier et al19 and Fickert et al8 used 3-
dimensional spheroids cultured from chondrocytes that
were harvested from the femoral head-neck junction (Chon-
drosphere; Co.Don AG). They were delivered without the
requirement for a scaffold. Fontana et al11 and Mancini and
Fontana24 used ACI with the chondrocytes isolated adja-
cent to the injury site and seeded onto a polymer scaffold
composed of polylactic/polyglycolic acid and polydioxanone
(Bioseed-C; Biotissue AG) before reimplantation.
The timing of delivery of chondrocytes varied among the
4 studies. Fickert et al8 reported chondrocyte delivery 4 to 6
weeks after harvesting. Mancini and Fontana24 reported a
delivery of approximately 3 weeks after harvesting,
whereas Fontana et al11 reported a delivery time of 2 to 6
weeks postoperatively. Körsmeier et al19 reported a deliv-
ery time of 5 to 10 weeks after harvest and described 95%
cell viability at the time of surgery. No study using ACI
reported the concentration of the chondrocytes delivered.
Fontana and de Girolamo12 and Mancini and Fontana24
both analyzed the use of AMIC. Both studies used a resorb-
able collagen I/III matrix (Chondroglide; Geistlich AG) in a
single surgical technique. Rafols et al40 and Redmond
et al41 both used PRP intraoperatively via percutaneous
intra-articular injection after wound closure. Rafols et al
used activated GPS III (Biomet), which is 7 to 8 times the
whole blood concentration. Redmond et al used Arthrex
TABLE 1
Patient Demographicsa
Lead
Author Journal Year
No. of
Patients Gender, n
Mean Age
(Range)
Follow-up,
mo
Chondral
Grading OA Severity
Fickert8 Arch Orthop Trauma Surg 2014 6 5 M, 1 F 33 (25-45) 12 ICRS 3 & 4 KL <2
Fontana12 Bone Joint J 2015 147 91 M, 56 F NR 60 OB 3 & 4 Tönnis grade <2
Fontana11 Arthroscopy 2012 30 12 M, 18 F 41 (20-53) 74 OB 3 & 4 Tönnis grade 2
Körsmeier19 Knee Surg Sports Traumatol
Arthrosc
2016 16 14 M, 2 F 31 (20-47) 16 OB 3 & 4 NR
LaFrance20 J Hip Preserv Surg 2015 35 NR 35 (18-63) 12 NA >1 mm joint
space
Mancini24 Int Orthop 2014 57 25 M, 32 F 36 60 OB 3 & 4 Tönnis grade <2
Mardones25 Muscles Ligaments Tendons J 2016 20 (29 hips) 10 M, 10 F 51 (39-60) 24 OB 3 & 4 Tönnis grades 2
& 3
Rafols40 Arthroscopy 2015 57 30 M, 27 F 35 (16-52) 24 NA Tönnis grade <2
Redmond41 Arthroscopy 2015 306 103 M, 203 F 36 24 NA NR
aF, female; ICRS, International Cartilage Repair Society classification; KL, Kellgren-Lawrence score; M, male; NA, not applicable; NR, not
recorded; OA, osteoarthritis; OB, Outerbridge classification.
44%
22%
33%
11%
ACI
AMIC
PRP
BM-MSC
Figure 2. Representation of the types of biologics used in the
included studies. Note that Mancini and Fontana24 used 2
biologics (AMIC vs ACI). ACI, autologous chondrocyte
implantation; AMIC, autologous matrix-induced chondrogen-
esis; BM-MSC, bone marrow–derived mesenchymal stem
cells; PRP, platelet-rich plasma (PRP).
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ACP Double-Syringe system (Arthrex), which is 2 to 3 times
the whole blood concentration. LaFrance et al20 injected
5 mL of PRP prepared with Accelerate Concentrating
System (Exactech Biologics) at the completion of the
procedure after evacuation of joint fluid. The platelet
concentration of this system is reported at 6 times the
whole blood concentration.
Finally, Mardones et al25 harvested BM-MSCs from the
anterior superior iliac spine at the time of initial arthros-
copy. Cells were then expanded to reach 20  106 cells and
checked with immunotypification via flow cytometry for
MSC markers. They were then injected once a week by
radioscopic guidance at the fourth, fifth, and sixth week
after harvesting.
Clinical Outcomes
The clinical outcomes of each study are described in
Table 3.
Complications
There were 6 studies that reported reoperation rates or
conversion to THA. Körsmeier et al19 reported a reopera-
tion rate of 12.5% at a mean follow-up of 16 months but no
conversions to THA during this time. Capsular adhesions
were removed in the reoperative cases, and both patients
were satisfied after repeat arthroscopy. Redmond et al41
reported a reoperation rate of 10.6% in the PRP group
(reasons not reported) and 6.4% in the control group
(P ¼ .2) and a THA conversion rate of 2.9% in the PRP
group and 5% in the control group (P ¼ .4) during their
2-year follow-up. Fontana and de Girolamo12 reported no
conversions to THA in the AMIC cohort and a 7.8% con-
version rate in the microfracture cohort at a mean follow-
up of 38 months. No reoperations or conversions to THA
were reported in the studies by Fickert et al,8 Mancini and
Fontana,24 or Fontana et al11 at 12-, 60-, and 74-month
follow-up, respectively. Mardones et al25 did not report
any reoperations but reported a THA conversion rate of
13.8% at mean follow-up of 24 months. No complications
were reported that were attributable to the delivery of the
biologics.
Quality Assessment
The results of the quality assessment of included studies
can be seen in Appendix Table A1. The mean percentage of
successfully answered questions from the assessment tool
was 67%. The level of evidence ranged from 1 to 4. The
mode level was 3.
DISCUSSION
The most significant findings were as follows: (1) a limited
number of high-level articles have reported the use of bio-
logics in the management of FAI; (2) variation existed in
the timing of delivery and concentration of biologics used;
(3) the use of ACI and AMIC appeared to deliver favorable
results for medium-sized chondral defects at short-term to
midterm follow-up compared with debridement or micro-
fracture; and (4) the use of PRP appeared to be ineffective
as adjuvant treatment of labral tears at short-term
follow-up.
Chondral injuries within the hip joint have been his-
torically problematic to treat. However, the introduction
of hip arthroscopy has allowed a spectrum of treatment
options to help manage these injuries. ACI has already
been proven to be an effective treatment in the short to
mid term for chondral lesions (>2 cm2) in the knee.5,43
All the studies included in this review that used ACI to
treat chondral injuries showed favorable patient-
reported outcome scores when compared with preopera-
tive scores and/or simple debridement or microfracture.
Mancini and Fontana24 evaluated patients up to 5 years
in 3 studies analyzing the use of ACI or AMIC and
showed maintained improvements in postoperative
TABLE 2
Study Design, Level of Evidence, Pathologic Condition, and Biologic Used in the Included Studiesa
Lead Author Study Design Pathologic Condition Location
Chondral Lesion,
cm2, mean (range) Biologic LOE
Fickert8 Case series FAI þ chondral defect Acetabulum/
femoral head
NR ACI 4
Fontana12 Prospective cohort FAI þ chondral defect Acetabulum 3.6 (2-8) AMIC vs MFx 3
Fontana11 Retrospective cohort FAI þ chondral defect Acetabulum/
femoral head
2.6 (2-3) ACI vs debridement 3
Körsmeier19 Case series FAI þ chondral defect Acetabulum 4.5 (3-6) ACI 3
LaFrance20 RCT FAI þ labral tear ± chondral defect Acetabulum NR PRP vs placebo 1
Mancini24 Prospective cohort FAI þ chondral defect Acetabulum 2.9 (2-4) ACI vs AMIC 3
Mardones25 Case series FAI þ chondral defect or OA NR NR BM-MSC 4
Rafols40 RCT FAI þ labral tear NR NA PRP vs placebo 2
Redmond41 Prospective cohort FAI þ labral tear ± chondral defect NR NR PRP vs LA 2
aACI, autologous chondrocyte implantation; AMIC, autologous matrix-induced chondrogenesis; BM-MSC, bone marrow–derived mesen-
chymal stem cells; FAI, femoroacetabular impingement; LA, local anesthetic; LOE, level of evidence; MFx, microfracture; NA, not applicable;
NR, not recorded; OA, osteoarthritis; PRP, platelet-rich plasma; RCT, randomized controlled trial.
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scores until final follow-up. Fontana and de Girolamo12
compared AMIC with microfracture and noted that the
microfracture cohort improved up to the 1-year follow-up
but that results deteriorated from 1 to 5 years. However,
this was not the case for the AMIC cohort, which
showed maintained results. Furthermore, the authors
stratified modified Harris Hip Scores into critical values
according to treatment and chondral lesion size and
found that defects larger than 4 cm2 correlated with a
2-fold incidence of low scoring in the microfracture group
but did not correlate with low scoring in the AMIC
cohort.
No study using adjuvant PRP to treat labral tears
showed improvements in postoperative outcome mea-
sures versus well-matched, controlled cohorts. Redmond
et al41 also included other hip-related conditions, such as
chondral lesions, gluteus medius tears, and ligament
teres tears, whereas LaFrance et al20 included patients
who underwent psoas muscle release and/or microfrac-
ture, and therefore the 3 studies using PRP are not
directly comparable. Furthermore, we noted significant
differences in the PRP concentrations used. This vari-
ability in the delivered concentration of biologic formula-
tions among studies in the current literature has already
been emphasized by the authors of this study in previous
reviews.7,31,42 Murray et al32 also highlighted the impor-
tance of selecting the correct formula of biologic most
suited to the microenvironment being treated. The con-
trasting results in our review between PRP and ACI/
AMIC may be due to delivery of subtherapeutic
concentrations of PRP, mismatches between the micro-
environment and the formulation, or both. Furthermore,
no study routinely used postoperative interval arthros-
copy to evaluate the macroscopic change in chondral
lesion, and previous evidence has shown that PRP is
relatively ineffective within the hip joint, particularly
in cases of chondral lesions.22
In our review, the study analyzing BM-MSCs was the
most complete in reporting biologic preparation, classifi-
cation, and concentration details. Details such as these
have previously been recommended by an expert consen-
sus as being pertinent to the interpretation of studies
involving biologics, and minimal reporting guidelines
have been established.30 Mardones et al25 did not com-
pare their results of intra-articular injection of BM-
MSCs to a control cohort but did show significant
improvements from preoperative to postoperative func-
tional scores at a mean follow-up of 24 months. Delivery
of the cells was staggered at 3 intervals, 1 week apart.
This timing of delivery has previously been shown to be
effective in animal studies.33
There were 2 studies that compared conversion rates
with total hip replacement between a biologics cohort
and a control cohort. Both studies reported higher rates
of THA in the nonbiologics cohort. In contrast, Redmond
et al41 reported higher rates of reoperation in the biolo-
gics cohort but did not power their study to detect differ-
ences in either reoperation rate or conversion to THA.
Fontana and de Girolamo12 reported that all patients
undergoing THA during their follow-up had recognized
TABLE 3
Clinical Outcomes After Biologics Intervention in Hip Arthroscopya
Lead Author Clinical Outcome
Fickert8 Statistically significant improvements in postoperative mHHS (mean improvement 23.5; P ¼ .04) and SF-36 physical score
(mean improvement 45.6; P < .01) at 12 months compared with preoperative scores but no improvement in SF-36 mental
score. Larger defect associated with poorer mHHS score but not lower NAHS. No significant differences in functional
outcomes with labral repair vs debridement.
Fontana12 Statistically improved mHSS for AMIC vs microfracture at 6 months and 2, 3, 4, and 5 years. Outcomes better for AMIC
regardless of the size of the lesion (<4 cm2 vs >4 cm2).
Fontana11 Statistically significant improvement in mHHS when ACI technique was used compared with debridement at all time points
from 6 months postoperatively to 5 years (P < .001).
Körsmeier19 Significantly improved scores compared with preoperative levels for NAHS and WOMAC at 6 weeks postoperatively and
“last follow-up” (mean, 16.1 months; range, 9.5-28.8 months).
LaFrance20 No significant difference in NAHS, mHHS, and HOS at any time point up to 12 months after surgery between the PRP
and placebo cohorts.
Mancini24 Significant improvement in mHHS at 6 months compared with preoperative score in both groups. Improvement maintained to
5 years. No statistical difference seen between AMIC vs ACI regardless of defect size.
Mardones25 Statistically significant improvements in preoperative to postoperative scores (mHHS [mean improvement 27], WOMAC
[mean improvement 23], Vail Hip Score [mean improvement 26], and VAS [from 6 to 2]) at final follow-up (mean, 24 months;
range, 13-36 months; P < .05).
Rafols40 No statistical difference in mHHS between the study group (PRP) and control group at 3, 6, and 24 months. Improved pain at 48
hours after surgery in the PRP group (P < .05). 100% labral integration in PRP group vs 94% in control seen on MRI at 6
months (P ¼ .08). No effusion seen on MRI at 6 months in 37% of PRP group vs 21% of control (P < .05).
Redmond41 No difference in HOS or NAHS at any time point between study group and control group. No difference in pain at 3
months postoperatively. Higher pain scores at 2 years in study group vs control at 2 years (3.4 vs 2.5; P ¼ .005).
aACI, autologous chondrocyte implantation; AMIC, autologous matrix-induced chondrogenesis; HOS, Hip Outcome Score; mHHS, mod-
ified Harris Hip Score; MRI, magnetic resonance imaging; NAHS, Nonarthritic Hip Score; PRP, platelet-rich plasma; SF-36, 36-Item Short
Form Health Survey; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
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risk factors for the development of degenerative change,
such as cam lesions with deep chondral lesions and
lesions with a diameter greater than 4 cm2.
Other outcome measures used to determine effectiveness
of biologic treatment were the postoperative presence of an
effusion on MRI scanning and the appearance of the chon-
dral lesion on second-look arthroscopy. Rafols et al40
reported a lack of hip joint effusion in 36.7% of the PRP
group compared with 21.1% of the placebo group at 6-
month follow-up on MRI scanning. Körsmeier et al19 per-
formed arthroscopy on 2 patients at 5 and 8 months after
ACI and reported hyaline-like cartilage in the area of pre-
vious implantation.
Elements of homogeneity were noted among the
included studies in our review. In particular, these
included a similar preoperative osteoarthritis status and
similar severity of chondral injuries, with most studies
using grade 3 or 4 on the Outerbridge classification.
Despite this, marked differences were seen, such as var-
iations in lesions, the treatment methods used (and
reported), the concentration of PRP, the timing of deliv-
ery, the outcome measures used, the presence of a con-
trol group, and follow-up time points.
Limitations
This review must be interpreted with recognition of its
limitations. Included were 3 low-level case series that
simply compared pre- and postoperative outcome mea-
sures. Given the well-recognized placebo effect in ortho-
paedic surgery studies, these types of studies must be
interpreted with caution.46 Furthermore, only one level
1, randomized controlled trial was included in our
review, and it did not report mid- to long-term follow-
up. Average follow-up in this review was 20.9 months,
and therefore overall failure rates and conversion to
THA may be underestimated.
A variety of lesions were treated within each study, and
some studies did not clearly report the exact surgical
interventions performed alongside the use of the biologic
agent. These details are important to include if the true
efficacy of the biologic intervention is to be determined.
The severity of osteoarthritis and the classification sys-
tems used to measure it varied between studies, with 1
study including patients with Tönnis grade 3 osteoarthri-
tis. Furthermore, it is recognized that advancing age lim-
its the function of stem cells.34 All studies in this review
included patients with a mean age older than 30 years,
and 2 studies included patients with a mean age older
than 40. There was paucity in the reporting of biologic
preparation and concentration between studies. When
these aspects were reported, variation was seen in the
concentration used and timing of delivery. Finally, a rela-
tively small number of studies were included in this
review, and 3 of the studies were performed in a single
center, with possible crossover in patients among those
studies. Despite these limitations, the current review
accurately outlines the current state of the existing liter-
ature in this area.
CONCLUSION
The current literature regarding biologic adjuncts in hip
arthroscopy is varied in quality, with only one level 1 study.
The use of ACI or AMIC for medium-sized chondral lesions
showed promising results in individual studies; however,
these studies were of lower quality. To enable comparisons
among future studies, investigators must ensure accuracy
in the reporting of the biologic preparations and formula-
tions used and homogeneity in the type and severity of
pathologic condition treated.
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APPENDIX
TABLE A1
Search Term Combinations
Search Search Terms
1 (“hip”[MeSH Terms] OR “hip”[All Fields]) “femoroacetabular”[All Fields] OR “impingement”[All Fields] OR (“arthroscopy”[MeSH
Terms] OR “arthroscopy”[All Fields]) AND (“platelet-rich plasma”[MeSH Terms] OR (“platelet-rich”[All Fields] AND “plasma”[All
Fields]) OR “platelet-rich plasma”[All Fields] OR (“platelet”[All Fields] AND “rich”[All Fields] AND “plasma”[All Fields]) OR
“platelet rich plasma”[All Fields])
2 (“hip”[MeSH Terms] OR “hip”[All Fields]) “femoroacetabular”[All Fields] OR “impingement”[All Fields] OR (“arthroscopy”[MeSH
Terms] OR “arthroscopy”[All Fields]) AND (“mesenchymal stem cells”[MeSH Terms] OR (“mesenchymal”[All Fields] AND
“stem”[All Fields] AND “cells”[All Fields]) OR “mesenchymal stem cells”[All Fields])
3 (“hip”[MeSH Terms] OR “hip”[All Fields]) “femoroacetabular”[All Fields] OR “impingement”[All Fields] OR (“arthroscopy”[MeSH
Terms] OR “arthroscopy”[All Fields]) AND (“bone marrow”[MeSH Terms] OR (“bone”[All Fields] AND ““marrow””[All Fields]) OR
““bone marrow””[All Fields]) AND aspirate [All Fields] AND concentrate[All Fields]
4 (““hip””[MeSH Terms] OR ““hip””[All Fields]) “femoroacetabular”[All Fields] OR “impingement”[All Fields] (““arthroscopy””[MeSH
Terms] OR ““arthroscopy””[All Fields]) AND (““intercellular signalling peptides and proteins””[MeSH Terms] OR
(““intercellular””[All Fields] AND ““signalling” All Fields] AND ““peptides””[All Fields] AND ““proteins””[All Fields]) AND
““intercellular signalling peptides and proteins””[All Fields] AND (““growth””[All Fields] AND ““factors””[All Fields]) AND
““growth factors””[All Fields])
5 (““hip””[MeSH Terms] OR ““hip””[All Fields]) AND “femoroacetabular”[All Fields] OR “impingement”[All Fields] OR
(““arthroscopy””[MeSH Terms] OR ““arthroscopy””[All Fields]) AND (““hyaluronic acid””[MeSH Terms] OR (““hyaluronic””[All
Fields] AND ““acid””[All Fields]) OR ““hyaluronic acid””[All Fields])
6 (“hip”[MeSH Terms] OR “hip”[All Fields]) AND “femoroacetabular”[All Fields] OR “impingement”[All Fields] OR
(“arthroscopy”[MeSH Terms] OR “arthroscopy”[All Fields]) AND autologous[All Fields] AND (“chondrocytes”[MeSH Terms] OR
“chondrocytes”[All Fields] OR “chondrocyte”[All Fields]) AND (“embryo implantation”[MeSH Terms] OR (“embryo”[All Fields]
AND “implantation”[All Fields]) OR “embryo implantation”[All Fields] OR “implantation”[All Fields])
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